Board of Directors

Ed is a partner at New Enterprise Associates (NEA), where he has invested in multiple companies with successful exits including Lumena (acquired by Shire), Ziarco (acquired by Novartis), Motus Therapeutics (acquired by Allergan), Amplyx (acquired by Pfizer), Inversago (acquired by Novo), Akouos (acquired by Lilly), Ra Pharma (acquired by UCB), and Plexxikon (acquired by Daiichi Sankyo), in addition to other private and public companies. Before joining NEA, Ed was executive vice president, corporate development and venture, at MedImmune and part of the leadership team that sold the company to AstraZeneca for $15.6 billion. Prior to MedImmune, he held roles of increasing responsibility at Inhale Therapeutic Systems and Glaxo Wellcome. Ed is a board member of multiple biotech and pharmaceutical companies, including gene therapy companies. He received a B.S. in chemistry from North Carolina State University.